Solid tumor
Conditions
Interventions
None listed
Sponsors
Ko Ryo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients with solid tumor who have received no prior chemotherapy or no more than two regimens of chemotherapy. 2) Anticancer therapy with regimens including immune checkpoint inhibitors or angiogenesis inhibitors (both antibody and tyrosine kinase inhibitors are acceptable) will be started within 28 days of enrollment. 3) At least 20 years old at the time of registration. 4) The treating investigator has determined that anticancer treatment is possible. 5) Survival of at least 24 weeks after enrollment is expected. 6) The patient's written consent to participate in the research has been obtained.
Exclusion criteria
Exclusion criteria: 1) Patients who are scheduled to receive only local or endocrine therapy as anticancer therapy. 2) Patients scheduled to receive chemoradiation therapy in which the chest area will be irradiated. 3) Patients with a history of treatment with immune checkpoint inhibitors or angiogenesis inhibitors. 4) Patients with acute coronary syndromes (myocardial infarction, angina pectoris), acute heart failure, or other urgent cardiac conditions that require treatment or procedures at the time of enrollment. 5) Patients with obvious cognitive decline or concomitant psychiatric disorders who are judged to be unable to participate in the study. 6) Patients who are judged by the treating investigators to be inappropriate to participate in this study for anti-cancer treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of cardiac hypofunction | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of cardiac hypofunction by drug Incidence of cardiac hypofunction by cancer type Relationship between other patient background and laboratory results at enrollment and incidence of cardiac hypofunction Incidence of symptomatic cardiac hypofunction Incidence of other cardiovascular events Status of treatment for cardiac hypofunction | — |
Contacts
Public ContactRyo Ko
Shizuoka Cancer Center
Outcome results
None listed